氨鲁米特治疗晚期乳腺癌

Aminoglutethimide in advanced breast cancer.

作者信息

Ceci G, Passalacqua R, Bisagni G, Bella M, Cocconi G

出版信息

Tumori. 1985 Oct 31;71(5):483-9. doi: 10.1177/030089168507100512.

Abstract

From July 1980 to June 1983, 61 postmenopausal women with progressive metastatic breast cancer were treated with aminoglutethimide, 250 mg 4 times daily, plus cortisone acetate, 25 mg twice daily. Of 51 evaluable patients, an objective remission was observed in 22 (43%) (partial remission in 19, complete in 3), stable disease in 14 (27%), and progressive disease in 15 (30%). The median duration of response was 60 weeks (range 12+; 94+). The response rate was higher when the dominant disease site was soft tissue (50%) or bone (56%) rather than viscera (29%). Side effects were common but usually slight and transient. Somnolence (69%), dizziness (41%), nausea (35%) and skin rash (27%) were the most frequent. Serum levels of gamma-GT, alkaline phosphatase and total cholesterol rose during aminoglutethimide treatment, whereas levels of uric acid and indirect bilirubin decreased. Aminoglutethimide plus cortisone acetate appears to be an active and relatively safe treatment in advanced breast cancer and may be recommended as second-line endocrine treatment.

摘要

1980年7月至1983年6月，61名患有进行性转移性乳腺癌的绝经后女性接受了氨鲁米特治疗，每日4次，每次250毫克，加醋酸可的松，每日2次，每次25毫克。在51名可评估的患者中，22名（43%）观察到客观缓解（19名部分缓解，3名完全缓解），14名（27%）病情稳定，15名（30%）病情进展。缓解的中位持续时间为60周（范围12 +；94 +）。当主要病变部位为软组织（50%）或骨（56%）而非内脏（29%）时，缓解率更高。副作用常见，但通常轻微且短暂。最常见的是嗜睡（69%）、头晕（41%）、恶心（35%）和皮疹（27%）。在氨鲁米特治疗期间，γ-谷氨酰转移酶、碱性磷酸酶和总胆固醇的血清水平升高，而尿酸和间接胆红素水平降低。氨鲁米特加醋酸可的松似乎是晚期乳腺癌的一种有效且相对安全的治疗方法，可推荐作为二线内分泌治疗。